MD1444B2 - Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi - Google Patents

Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi

Info

Publication number
MD1444B2
MD1444B2 MD97-0009A MD970009A MD1444B2 MD 1444 B2 MD1444 B2 MD 1444B2 MD 970009 A MD970009 A MD 970009A MD 1444 B2 MD1444 B2 MD 1444B2
Authority
MD
Moldova
Prior art keywords
patient
receptor
organs
inducing
methods
Prior art date
Application number
MD97-0009A
Other languages
English (en)
Russian (ru)
Other versions
MD970009A (ro
Inventor
Randolph J. Noelle
Fiona H. Durie
David C. Parker
Michael C. Appel
Nancy E. Philips
John P. Mordes
Dale L. Grenier
Aldo A. Rossini
Original Assignee
Trustees Of Dartmouth College
University Of Massachusetts Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Dartmouth College, University Of Massachusetts Medical Center filed Critical Trustees Of Dartmouth College
Publication of MD970009A publication Critical patent/MD970009A/ro
Publication of MD1444B2 publication Critical patent/MD1444B2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Invenţia se referă la domeniul medicinei, în special la transplantologie, şi poate fi utilizată pentru transplantul de organe sau ţesuturi la etapa preparativă.Esenţa invenţiei constă în aceea că pacientului i se administrează o celulă alogenă sau xenogenă care determină antigenii donatorului şi care are un ligand pe suprafaţa celulelor ce interacţionează cu un receptor pe suprafaţa unei celule T a pacientului, care mediază funcţia efectorului de ajutor dependent de contact şi a unui antagonist al receptorului care inhibă interacţiunea ligandului cu receptorul. De asemenea este propusă o metodă pentru tratarea diabetului care cuprinde administrarea unui pacient a celulelor alogene sau xenogene care determină antigenii donatorului antagonist gp39 şi a insulelor pancreatice.
MD97-0009A 1994-04-25 1995-04-25 Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi MD1444B2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/234,987 US5683693A (en) 1994-04-25 1994-04-25 Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PCT/US1995/004832 WO1995028957A2 (en) 1994-04-25 1995-04-25 Methods for inducing t cell tolerance to a tissue or organ graft

Publications (2)

Publication Number Publication Date
MD970009A MD970009A (ro) 1999-01-31
MD1444B2 true MD1444B2 (ro) 2000-04-30

Family

ID=22883593

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0009A MD1444B2 (ro) 1994-04-25 1995-04-25 Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi

Country Status (34)

Country Link
US (4) US5683693A (ro)
EP (2) EP1530973A3 (ro)
JP (1) JP2974415B2 (ro)
KR (1) KR100468330B1 (ro)
CN (1) CN1134266C (ro)
AP (1) AP764A (ro)
AT (1) ATE288281T1 (ro)
AU (1) AU710925B2 (ro)
BG (1) BG62121B1 (ro)
BR (1) BR9507509A (ro)
CA (1) CA2188672A1 (ro)
CZ (1) CZ291266B6 (ro)
DE (1) DE69533984T2 (ro)
DK (1) DK0757557T3 (ro)
EE (1) EE03516B1 (ro)
ES (1) ES2237757T3 (ro)
FI (1) FI118792B (ro)
GE (1) GEP20022648B (ro)
HU (1) HU221752B1 (ro)
IS (1) IS2118B (ro)
LT (1) LT4309B (ro)
LV (1) LV11785B (ro)
MD (1) MD1444B2 (ro)
NO (2) NO319787B1 (ro)
NZ (1) NZ284905A (ro)
OA (1) OA10591A (ro)
PL (1) PL180031B1 (ro)
PT (1) PT757557E (ro)
RO (1) RO114743B1 (ro)
RU (1) RU2169009C2 (ro)
SI (1) SI9520057A (ro)
SK (1) SK136996A3 (ro)
UA (1) UA44892C2 (ro)
WO (1) WO1995028957A2 (ro)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
PT721469E (pt) * 1993-09-02 2000-04-28 Dartmouth College Anticorpos anti-gp39 e suas utilizacoes2
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
EP1754490A3 (en) * 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
DE69835965T2 (de) * 1997-06-20 2007-06-14 Biogen Idec Ma Inc., Cambridge CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
HUP0103107A2 (hu) * 1998-07-30 2001-11-28 Regents Of The University Of Minnesota Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) * 1999-11-25 2001-01-27 Камакин Владислав Владимирович Способ индивидуального подбора оптимального питания человека
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
RU2270691C2 (ru) 2000-05-12 2006-02-27 Бет Израел Диконесс Медикал Сентер, Инк. Композиции и способы достижения иммунной супрессии
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
WO2002078743A1 (en) * 2001-02-16 2002-10-10 University Of Rochester Compositions and methods for reducing tranfusion reactions
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DE10231655A1 (de) * 2002-07-12 2004-02-26 Blasticon Biotechnologische Forschung Gmbh Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US20070041971A1 (en) * 2003-07-07 2007-02-22 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
DK1707627T3 (da) * 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (en) * 2005-12-07 2007-06-13 Schuler, Gerold, Prof. Dr. Method for the direct culture of dendritic cells without a preceding centrifugation step
DK1988882T3 (en) * 2006-03-02 2015-02-23 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
FR2934140B1 (fr) * 2008-07-25 2010-09-03 Seb Sa Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
US20100329983A1 (en) 2009-06-26 2010-12-30 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
HK1245010A1 (zh) 2014-12-10 2018-08-24 明尼苏达大学董事会 用於治疗疾病的遗传修饰的细胞、组织和器官
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) * 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
EP0408859B1 (en) * 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to activated endothelial cells
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
BR9206649A (pt) * 1991-10-18 1995-10-24 Cantab Pharma Res Processo para o tratamento in vitro de um rim antes do transplante em um receptor humano
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
NO933860L (no) * 1992-10-30 1994-05-02 Bristol Myers Squibb Co Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon
PT721469E (pt) * 1993-09-02 2000-04-28 Dartmouth College Anticorpos anti-gp39 e suas utilizacoes2
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Carpenter C. B. Immunosuppression in Organ Transplantation. The New England Journal of Medicine. Massachusetts Medical Society, 1990 vol. 322, № 17, p. 1224 *
Faseb Journal, Abstracts, Part I, vol. 8, № 4, March 15, 1994, p. a 477, abstract № 2763 *
Kahan B. D. Immunosuppressive Therapy. Current Opinion In Immunology, 1992, vol. 4, № 5, p. 553 *
Roark J.H. et. al. Prolongation of Rat Pancreatic Islet Allograf Survival by Anti-CD2 Monoclonal Antibody Treatment. Transplantation. Williams & Wilkins, 1992, vol. 54, № 6, p. 1098 *
Robertson R. P. "Pancreatic and Islet Transplantation for Diabets-Cures or Curiosities". The New England Journal of Medicine. Massachusetts Medical Society, 1992, vol. 327, №. 26, p. 1861 *

Also Published As

Publication number Publication date
HU9602924D0 (en) 1996-12-30
CA2188672A1 (en) 1995-11-02
DE69533984T2 (de) 2006-04-27
OA10591A (en) 2002-07-15
SI9520057A (sl) 1998-06-30
JP2974415B2 (ja) 1999-11-10
EP0757557B1 (en) 2005-02-02
US20050152897A1 (en) 2005-07-14
PT757557E (pt) 2005-05-31
LV11785A (lv) 1997-06-20
US5683693A (en) 1997-11-04
IS2118B (is) 2006-06-15
UA44892C2 (uk) 2002-03-15
PL317022A1 (en) 1997-03-03
HU221752B1 (hu) 2002-12-28
AP764A (en) 1999-09-16
AU2358595A (en) 1995-11-16
US7501124B2 (en) 2009-03-10
CN1150760A (zh) 1997-05-28
NZ284905A (en) 2004-10-29
AU710925B2 (en) 1999-09-30
NO319787B1 (no) 2005-09-12
NO20051182L (no) 1996-12-23
US5902585A (en) 1999-05-11
JPH09512271A (ja) 1997-12-09
KR100468330B1 (ko) 2005-12-30
NO964440L (no) 1996-12-23
US6375950B1 (en) 2002-04-23
AP9600906A0 (en) 1997-01-31
EE03516B1 (et) 2001-10-15
BG62121B1 (bg) 1999-03-31
HUT76091A (en) 1997-06-30
FI118792B (fi) 2008-03-31
DK0757557T3 (da) 2005-05-23
ES2237757T3 (es) 2005-08-01
PL180031B1 (pl) 2000-12-29
SK136996A3 (en) 1999-01-11
EP1530973A3 (en) 2006-12-27
BG100991A (en) 1998-01-30
EP0757557A1 (en) 1997-02-12
LT96165A (en) 1997-11-25
GEP20022648B (en) 2002-03-25
DE69533984D1 (de) 2005-03-10
NO964440D0 (no) 1996-10-18
EE9600162A (et) 1997-06-16
MD970009A (ro) 1999-01-31
FI964272A7 (fi) 1996-12-19
WO1995028957A3 (en) 1995-11-23
CN1134266C (zh) 2004-01-14
IS4378A (is) 1996-10-22
LT4309B (lt) 1998-03-25
LV11785B (en) 1998-02-20
CZ291266B6 (cs) 2003-01-15
ATE288281T1 (de) 2005-02-15
RU2169009C2 (ru) 2001-06-20
WO1995028957A2 (en) 1995-11-02
BR9507509A (pt) 1997-02-02
CZ312596A3 (en) 1997-03-12
RO114743B1 (ro) 1999-07-30
FI964272A0 (fi) 1996-10-23
EP1530973A2 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
FI104732B (fi) Menetelmä transplantaatiossa käyttökelpoisen solun tai kudoksen valmistamiseksi
Grand et al. Axonal regeneration after cold preservation of nerve allografts and immunosuppression with tacrolimus in mice
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
JP2011037865A (ja) 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物
ATE212230T1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
DK0621786T3 (da) Induceret tolerance over for xenotransplantater
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
NO992569D0 (no) FremgangsmÕter for Õ hindre podingsforkastelse i transplantasjon og for fremstilling av en universell genterapi vertcelle ved Õ anvende lymfocytt aktivering (LAG-3)
Siemionow et al. Advances in the development of experimental composite tissue transplantation models
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
WO1996032137B1 (en) Methods of inducing immune tolerance using immunotoxins
Hornung et al. Specific tissue and tumor responses of chimpanzees following immunization against human melanoma
Gambacorti-Passerini et al. Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with Mafosfamide
Gilhar et al. Description of and treatment to inhibit the rejection of human split-thickness skin grafts by congenitally athymic (nude) rats
Black et al. Cyclosporine and Skin Allografts for the Treatment of Thermal Injury: II. Development of an Experimental Massive Third-Degree Burn Model Demonstrating Extensive Graft Survival
NO983917L (no) Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus
CA2473749A1 (en) Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof
Szabo et al. Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
Markmann et al. Prevention of recurrent diabetes in BB rats after islet transplantation by monoclonal antibody therapy
MX9605051A (es) Metodos para inducir la tolerancia de celulas t a un injerto u organo.
Zhu et al. Immunomodulatory effect of mesenchymal stromal cell overexpressing HLA-G1 in cell-based therapy for myocardial infarction
JPH06298654A (ja) 抗原特異的免疫抑制剤

Legal Events

Date Code Title Description
PD99 Pending application